Chemistry:Frexalimab

From HandWiki
Short description: Monoclonal antibody
Frexalimab
Monoclonal antibody
TypeWhole antibody
TargetCD40 ligand
Clinical data
AHFS/Drugs.comMonograph
License data
Legal status
Legal status
  • Investigational
Identifiers
ChemSpider
  • none
KEGG

Frexalimab (SAR441344) is a second-generation monoclonal antibody that inhibits CD40 ligand. It is in development by Sanofi for the treatment of relapsing multiple sclerosis.[1][2][3][4][5][6]

References

  1. Carvalho, Thiago (5 July 2023). "Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis" (in en). Nature Medicine 29 (8): 1882–1883. doi:10.1038/d41591-023-00060-4. https://www.nature.com/articles/d41591-023-00060-4. 
  2. Niebel, Dennis; de Vos, Luka; Fetter, Tanja; Brägelmann, Christine; Wenzel, Jörg (July 2023). "Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions". American Journal of Clinical Dermatology 24 (4): 521–540. doi:10.1007/s40257-023-00774-8. 
  3. Ritter, Jacob; Chen, Yidan; Stefanski, Ana-Luisa; Dörner, Thomas (November 2022). "Current and future treatment in primary Sjögren's syndrome – A still challenging development". Joint Bone Spine 89 (6): 105406. doi:10.1016/j.jbspin.2022.105406. 
  4. Fadul, Camilo E.; Mao-Draayer, Yang; Ryan, Kathleen A.; Noelle, Randolph J.; Wishart, Heather A.; Channon, Jacqueline Y.; Kasper, Isaac R.; Oliver, Brant et al. (November 2021). "Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis". Neurology - Neuroimmunology Neuroinflammation 8 (6): e1096. doi:10.1212/NXI.0000000000001096. 
  5. Vial, G.; Gensous, N.; Duffau, P. (October 2021). "L’axe CD40-CD40L : implications actuelles et futures en immunologie clinique". La Revue de Médecine Interne 42 (10): 722–728. doi:10.1016/j.revmed.2021.02.005. 
  6. Cree, Bruce A.C.; Hartung, Hans-Peter; Barnett, Michael (June 2022). "New drugs for multiple sclerosis: new treatment algorithms". Current Opinion in Neurology 35 (3): 262–270. doi:10.1097/WCO.0000000000001063.